Trial Profile

Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Docetaxel
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms VARGADO
Sponsors Boehringer Ingelheim

Most Recent Events

19 Feb 2025 Planned End Date changed from 31 Jan 2025 to 30 Jun 2025.
19 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2025.
14 Dec 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com